Loudon Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Loudon Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Hold	485	–	–	0.12%	90
2026 Q1	$217K	Hold	485	–	–	0.12%	94
2025 Q4	$220K	Buy	+485	New	+$209K	0.11%	91
2025 Q3	–	Sell	-485	Closed	-$216K	–	103
2025 Q2	$216K	Hold	485	–	–	0.12%	97
2025 Q1	$235K	Buy	+485	New	+$226K	0.13%	90
2024 Q4	–	Sell	-485	Closed	-$226K	–	101
2024 Q3	$226K	Hold	485	–	–	0.12%	95
2024 Q2	$227K	Hold	485	–	–	0.13%	95
2024 Q1	$203K	Buy	+485	New	+$205K	0.12%	95
2023 Q1	–	Sell	-695	Closed	-$201K	–	93
2022 Q4	$201K	Sell	695 -340	-33%	-$104K	0.14%	89
2022 Q3	$300K	Sell	1,035 -1,165	-53%	-$335K	0.24%	76
2022 Q2	$620K	Buy	2,200 +20	+0.9%	+$5.35K	0.46%	58
2022 Q1	$569K	Buy	2,180 +675	+45%	+$160K	0.37%	61
2021 Q4	$330K	Buy	+1,505	New	+$293K	0.21%	78

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Loudon Investment Management's VRTX Position: Q2 2026 in Review

Loudon Investment Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 485 shares worth $241K. The position accounts for 0.12% of the portfolio, ranked #90.

Loudon Investment Management first reported a position in VRTX in Q4 2021 and has held it in 13 quarters since. The position peaked at $620K in Q2 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Loudon Investment Management held 485 shares of Vertex Pharmaceuticals worth $241K as of Q2 2026.
Loudon Investment Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.12% of Loudon Investment Management's portfolio in Q2 2026, its #90 holding.
Loudon Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
Loudon Investment Management's Vertex Pharmaceuticals position peaked at $620K in Q2 2022.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Loudon Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.